JP2012527875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012527875A5 JP2012527875A5 JP2012512351A JP2012512351A JP2012527875A5 JP 2012527875 A5 JP2012527875 A5 JP 2012527875A5 JP 2012512351 A JP2012512351 A JP 2012512351A JP 2012512351 A JP2012512351 A JP 2012512351A JP 2012527875 A5 JP2012527875 A5 JP 2012527875A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- antigen
- protein according
- receptor
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 16
- 108091000831 antigen binding proteins Proteins 0.000 claims 16
- 230000004927 fusion Effects 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18186509P | 2009-05-28 | 2009-05-28 | |
| US61/181,865 | 2009-05-28 | ||
| PCT/EP2010/057227 WO2010136480A1 (en) | 2009-05-28 | 2010-05-26 | Antigen-binding proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012527875A JP2012527875A (ja) | 2012-11-12 |
| JP2012527875A5 true JP2012527875A5 (enExample) | 2013-07-11 |
Family
ID=42332502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012512351A Pending JP2012527875A (ja) | 2009-05-28 | 2010-05-26 | 抗原結合タンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120070436A1 (enExample) |
| EP (1) | EP2435477A1 (enExample) |
| JP (1) | JP2012527875A (enExample) |
| CA (1) | CA2763439A1 (enExample) |
| WO (1) | WO2010136480A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014014418A2 (pt) * | 2011-12-15 | 2019-09-24 | Nat Res Council Canada | proteínas de fusão fc de receptor igf solúvel e usos das mesmas |
| JP2015509714A (ja) * | 2012-02-22 | 2015-04-02 | エヌヴィーアイピー プロプライエタリー リミテッド | 腫瘍壊死因子レセプター融合タンパク質及び前記タンパク質を使用する方法 |
| CN102585016B (zh) * | 2012-03-06 | 2014-06-04 | 江苏健德生物药业有限公司 | 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用 |
| CN103045646B (zh) * | 2012-12-27 | 2015-02-25 | 中国人民解放军军事医学科学院基础医学研究所 | 共表达两个独立的抗关节炎分子TNFR-Fc和CTLA4-FasL的重组腺相关病毒载体及其构建方法与应用 |
| CN103232542B (zh) * | 2013-02-01 | 2015-05-13 | 殷勇 | 一种双靶标嵌合蛋白 |
| WO2014168715A1 (en) * | 2013-04-08 | 2014-10-16 | R-Pharm Overseas, Inc. | B7 ligands/cd20 inhibitor composition and use thereof |
| CN104231086B (zh) * | 2013-08-27 | 2019-12-13 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
| CN105916883B (zh) * | 2014-01-28 | 2019-12-03 | 北京韩美药品有限公司 | 双功能融合蛋白及其制备方法和用途 |
| CN107074976B (zh) * | 2014-11-04 | 2020-10-09 | 北京韩美药品有限公司 | 同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白 |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| CN111423512B (zh) * | 2019-01-10 | 2024-01-05 | 北京比洋生物技术有限公司 | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 |
| US11414785B2 (en) | 2019-08-13 | 2022-08-16 | Waters Technologies Corporation | Affinity resins and sample preparation devices based on cartilaginous fish IgNAR derived binding domains |
| PH12022552164A1 (en) * | 2020-02-19 | 2023-11-29 | United Biomedical Inc | Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19) |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| EP4608443A1 (en) * | 2022-10-25 | 2025-09-03 | The Regents of the University of California | Methods for sensitizing response to an immunotherapy |
| US12240888B1 (en) * | 2024-04-29 | 2025-03-04 | QILU Pharmaceutical, Co., Ltd. | Composition comprising aflibercept and a variant thereof, and related methods and uses |
| WO2026052756A1 (en) * | 2024-09-05 | 2026-03-12 | Ablynx Nv | Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9712670A (pt) * | 1996-10-25 | 1999-10-19 | Biogen Inc | Receptores para linfotoxina-beta, anticorpos anti-receptor para linfotoxina, e anticorpos antiligante de linfotoxina como agentes terapêuticos para o tratamento de doencas imunológicas |
| US7255854B1 (en) * | 1996-10-25 | 2007-08-14 | Biogen, Inc. | Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases |
| US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| GB0230203D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
-
2010
- 2010-05-26 WO PCT/EP2010/057227 patent/WO2010136480A1/en not_active Ceased
- 2010-05-26 EP EP10720783A patent/EP2435477A1/en not_active Withdrawn
- 2010-05-26 JP JP2012512351A patent/JP2012527875A/ja active Pending
- 2010-05-26 US US13/322,200 patent/US20120070436A1/en not_active Abandoned
- 2010-05-26 CA CA2763439A patent/CA2763439A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107686520B (zh) | 抗pd-l1纳米抗体及其应用 | |
| JP2012501669A5 (enExample) | ||
| AU2019256431B2 (en) | Anti-ror antibody constructs | |
| JP2017008046A5 (enExample) | ||
| JP2021502810A5 (enExample) | ||
| JP2017079785A5 (enExample) | ||
| JP2016511277A5 (enExample) | ||
| JP2012507994A5 (enExample) | ||
| JP2018530331A5 (enExample) | ||
| JP2012518398A5 (enExample) | ||
| RU2019115610A (ru) | Антитела и полипептиды, направленные против cd127 | |
| JP2017529067A5 (enExample) | ||
| JP2014500009A5 (enExample) | ||
| JP2023505492A5 (enExample) | ||
| JP2015508757A5 (enExample) | ||
| JP2018512145A5 (enExample) | ||
| JP2018502060A5 (enExample) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2014502955A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2014530611A5 (enExample) | ||
| JP2014511680A5 (enExample) | ||
| JP2016526014A5 (enExample) | ||
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| JP2013541335A5 (enExample) |